Across TCGA pan-cancer cohorts, SREBF2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SREBF2 data layer compared with 28 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher SREBF2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SREBF2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KIRP, UCEC, and COAD are the cancer types where SREBF2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	OS	Median	II,III,IV	0.141	0.772	<.001	27	view →
UCEC	DFS	Median	All	0.826	0.629	.014	10	view →
COAD	DFS	Median	II,III,IV	0.192	0.687	.016	9	view →
SARC	DFS	Median	All	0.115	0.635	<.001	6	view →
LUSC	OS	Median	All	0.196	0.724	.049	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: SREBF2 tumor-vs-normal RNA expression · all SREBF2 data types